← board
HIND
distress 6/10 · elevated risk$2.120%today-86% from 52w high
Lead: malignant fungating wounds
Revenue
pre-revenue
Liquidity
$9M
Runway
2.8 yrs
Shares 1y
+161%
Price & events
-27.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.0%
1D
-3.2%
1W
+0.0%
1M
-6.2%
3M
-33.5%
6M
-84.2%
1Y
-99.8%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $14.88M
- Volume
- 1.76K
- 52 Week Range
- $1.89 – $15.68
- Total Shares
- 7.02M
- Float Shares
- 3.25M
- Short %
- 0.78%
- % Held by Insiders
- 52.88%
- % Held by Institutions
- 1.52%
- RVOL
- 0.11x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- H1 2028Guided 55%readoutPhase 3VT-1953 · Phase 3 study completionSEC 8-K
- 2026-02-25partnershipAgreement amended to extend outside date to March 8, 2026.SEC 8-K
- 2026-02-20partnershipVyome subsidiary Livechain acquires senior secured convertible note of Humanyze from Remus Capital via Notes Purchase and Exchange Agreement.SEC 8-K
- fourth quarter of 2025trial initiationsecondaryVT-1953 · Planning to have discussions with FDA on pivotal trial protocolSEC 8-K
- 2025-09-29partnershipAcquired Oculo, Inc., an AI startup, to launch AI psychiatrist for reducing inflammation.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — malignant fungating wounds
- none identified
Recent news
- 2026-07-22Price to sales forward of Vyome Holdings, Inc. – NASDAQ:HIND - TradingView
- 2026-07-11Vyome (HIND) Proxy Filing Summary - Quartr
- 2026-07-11Vyome (HIND) Q4 2025 earnings summary - Quartr
- 2026-07-11Vyome (HIND) Q3 2025 earnings summary - Quartr
- 2026-07-11Vyome (HIND) Proxy Filing Summary - Quartr
- 2026-06-25HIND Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-05-28Press Release: Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet - Moomoo
- 2026-05-28Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.